JPS60190720A - アシル基を有する細胞正常化抗腫瘍剤 - Google Patents
アシル基を有する細胞正常化抗腫瘍剤Info
- Publication number
- JPS60190720A JPS60190720A JP59044972A JP4497284A JPS60190720A JP S60190720 A JPS60190720 A JP S60190720A JP 59044972 A JP59044972 A JP 59044972A JP 4497284 A JP4497284 A JP 4497284A JP S60190720 A JPS60190720 A JP S60190720A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- acyl group
- antitumor agent
- agent
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002252 acyl group Chemical group 0.000 title abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 10
- 239000000706 filtrate Substances 0.000 abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 3
- 239000001888 Peptone Substances 0.000 abstract description 3
- 108010080698 Peptones Proteins 0.000 abstract description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract description 3
- 229910000365 copper sulfate Inorganic materials 0.000 abstract description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 abstract description 3
- 239000000287 crude extract Substances 0.000 abstract description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 abstract description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 abstract description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 abstract description 3
- 235000019319 peptone Nutrition 0.000 abstract description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract description 3
- 239000011780 sodium chloride Substances 0.000 abstract description 3
- 229940041514 candida albicans extract Drugs 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract description 2
- 235000019341 magnesium sulphate Nutrition 0.000 abstract description 2
- 239000012138 yeast extract Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 244000063299 Bacillus subtilis Species 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 150000002596 lactones Chemical group 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical group OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000156473 Vallaris heynei Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001793 charged compounds Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59044972A JPS60190720A (ja) | 1984-03-09 | 1984-03-09 | アシル基を有する細胞正常化抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59044972A JPS60190720A (ja) | 1984-03-09 | 1984-03-09 | アシル基を有する細胞正常化抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60190720A true JPS60190720A (ja) | 1985-09-28 |
| JPS6232174B2 JPS6232174B2 (enrdf_load_stackoverflow) | 1987-07-13 |
Family
ID=12706387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59044972A Granted JPS60190720A (ja) | 1984-03-09 | 1984-03-09 | アシル基を有する細胞正常化抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60190720A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999006441A1 (es) * | 1997-07-29 | 1999-02-11 | Chacon Pabon, Rafael | Producto proteico, procedimiento para su preparacion, composiciones que lo contienen, y su uso en medicamentos |
-
1984
- 1984-03-09 JP JP59044972A patent/JPS60190720A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999006441A1 (es) * | 1997-07-29 | 1999-02-11 | Chacon Pabon, Rafael | Producto proteico, procedimiento para su preparacion, composiciones que lo contienen, y su uso en medicamentos |
| ES2142729A1 (es) * | 1997-07-29 | 2000-04-16 | Chacon Pabon Rafael | Producto proteico, procedimiento para su preparacion, composiciones que lo contienen, y su uso en medicamentos. |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6232174B2 (enrdf_load_stackoverflow) | 1987-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5925599B2 (ja) | 新生理活性物質モナコリンｋおよびその製造法 | |
| JPH0285296A (ja) | Ｆｒ９０１２２８物質およびその製造法 | |
| CN110218200B (zh) | 一种红树内生真菌中环缩肽化合物及其制备方法与应用 | |
| JPS60190720A (ja) | アシル基を有する細胞正常化抗腫瘍剤 | |
| JPH0641067A (ja) | 新規カルパイン阻害物質ｋｐ−１２４１及びその製造法 | |
| Heding | Radioactive myoinositol: incorporation into streptomycin | |
| CA2213285A1 (en) | Novel polyene antibiotics, 3874 h1 to h6, processes for their preparation and use | |
| JP2695225B2 (ja) | 新規物質ｕｃｔ−１００３ | |
| JP4380913B2 (ja) | 新規ｆｔ−０５５４物質及びその製造法 | |
| JP4105805B2 (ja) | 新規抗真菌活性物質ｐｆ１１６３ａ物質およびｐｆ１１６３ｂ物質、それらの製造法ならびにそれらを有効成分とする抗真菌剤 | |
| CN117736884B (zh) | 一株赭曲霉f8509及其应用 | |
| JPH026518B2 (enrdf_load_stackoverflow) | ||
| JPS5831992A (ja) | 新規生理活性物質ｋ−４およびその製造法 | |
| Naik et al. | Fermentation, isolation, purification and biological activity of SJA-95, a heptaene polyene macrolide antibiotic produced by the Streptomyces sp. strain S24 | |
| JP2576883B2 (ja) | Ｓ−６３２−ｂ▲下１▼およびｓ−６３２−ｂ▲下２▼物質 | |
| JPH02138996A (ja) | カンタキサンチンの製造法 | |
| JPH0676434B2 (ja) | 新規抗生物質ｐｆ１０３２物質ならびにその製造法 | |
| JPH08239339A (ja) | 化合物クラソインａおよびｂ並びにその製造法 | |
| JP2856379B2 (ja) | 蛋白質脱リン酸化酵素阻害剤及び抗腫瘍剤 | |
| JPH08127583A (ja) | Ｆｏ−２０４７物質およびその製造法 | |
| JPS6021997B2 (ja) | アシル基を有するペプチド、微生物によるその製法及びそれからなる環状アデノシン３′，５′−モノリン酸ホスホジエステラ−ゼ阻害剤 | |
| JPH0660170B2 (ja) | 抗生物質調整の中間体デイフイコール | |
| JPS5995253A (ja) | アシル基を有するペプチド、微生物によるその製法及びそれからなる環状アデノシン３′，５′−モノリン酸ホスホジエステラ−ゼ阻害剤 | |
| JPS6311341B2 (enrdf_load_stackoverflow) | ||
| JPS58149688A (ja) | 補酵素ｑ↓１↓０の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |